Kintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022PRNewsWire • 12/01/22
Kintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementPRNewsWire • 11/30/22
Kintara Therapeutics Granted Fast Track Designation from FDA for REM-001 for Cutaneous Metastatic Breast CancerPRNewsWire • 11/28/22
Kintara Therapeutics Presents Three Posters at the 2022 Society for Neuro-Oncology Annual MeetingPRNewsWire • 11/18/22
Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 11/09/22
Kintara Therapeutics Pauses REM-001 Program to Conserve Funds to Support VAL-083 International Registrational StudyPRNewsWire • 10/19/22
Kintara Therapeutics Announces Fiscal 2022 Financial Results and Provides Corporate UpdatePRNewsWire • 09/27/22
Kintara Therapeutics Announces Three Abstracts Have Been Accepted for the 2022 Society for Neuro-Oncology Annual MeetingPRNewsWire • 09/08/22
Kintara Therapeutics Receives Study May Proceed Letter from the FDA for REM-001 for Cutaneous Metastatic Breast CancerPRNewsWire • 08/09/22
Kintara Therapeutics Enters Into Equity Purchase Agreement for Up to $20 Million with Lincoln Park CapitalPRNewsWire • 08/03/22
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare ConferencePRNewsWire • 06/21/22
Kintara Therapeutics Granted Fast Track Designation from the FDA for VAL-083 for Newly-Diagnosed GlioblastomaPRNewsWire • 06/15/22
Kintara Announces First European Site Activation in Switzerland in GCAR Phase 2/3 Clinical Trial for GlioblastomaPRNewsWire • 05/27/22
Kintara Therapeutics Announces Fiscal 2022 Third Quarter Financial Results and Provides Corporate UpdatePRNewsWire • 05/13/22